Added to YB: 2025-09-12
Pitch date: 2025-09-10
PTGX [bullish]
Protagonist Therapeutics, Inc.
+64.94%
current return
Author Info
BiotechBonanza shares takes on biotech with a heavy focus on special situations. Sign up for the newsletter.
Company Info
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
Market Cap
$5.3B
Pitch Price
$57.81
Price Target
173.00 (+81%)
Dividend
N/A
EV/EBITDA
203.46
P/E
117.48
EV/Sales
22.09
Sector
Biotechnology
Category
growth
PTGX: A JNJ bond trading below face value with free call options attached!
PTGX: Oral IL-23 drug Icotrokinra (JNJ partner) showing superior efficacy vs injectables in psoriasis/UC, targeting $15B+ market. JNJ guides 2x consensus at $1.4B 2028 sales. 6-10% royalties could yield $400-900M annually. Rusfertide (Takeda) approval H2 2026, opt-out pays $400M. Pipeline includes oral IL-17 (LLY paid $2.4B for similar asset). Base case $67.5/share on approved drugs alone, current $58.
Read full article (18 min)